2.58

3.20% 0.08

After Hours: 2.58

Tscan Therapeutics Inc (TCRX)

Overview News Price History Financials Discussions Forecast

Tscan Therapeutics Inc stock is traded at $2.58, with a volume of 151.93K. It is up +3.20% in the last 24 hours and down -14.00% over the past month. TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Previous Close:

$2.50

Open:

$2.53

24h Volume:

151.93K

Relative Volume:

0.38

Market Cap:

$146.86M

Revenue:

$21.05M

Net Income/Loss:

$-89.22M

P/E Ratio:

-1.4413

EPS:

-1.79

Net Cash Flow:

$-64.50M

1W Performance:

+0.78%

1M Performance:

-14.00%

6M Performance:

-63.25%

1Y Performance:

-48.19%

1-Day Range:

$2.473

$2.64

1-Week Range:

$2.39

$2.64

52-Week Range:

$2.305

$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name

Tscan Therapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (678)

Phone

857-399-9500

Address

880 WINTER STREET, WALTHAM

Employee

199

Twitter

Next Earnings Date

Latest SEC Filings

TCRX's Discussions on Twitter

Compare TCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TCRX Tscan Therapeutics Inc	2.58	146.86M	21.05M	-89.22M	-64.50M	-1.79
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-16-24	Initiated	BTIG Research	Buy
May-13-24	Initiated	Needham	Buy
Jun-22-23	Initiated	Wedbush	Outperform

Tscan Therapeutics Inc Stock (TCRX) Latest News

Jan 21, 2025

Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Jan 21, 2025

Jan 17, 2025

TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN

Jan 17, 2025

TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St

Jan 17, 2025

Jan 11, 2025

Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN

Jan 11, 2025

Jan 10, 2025

TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World

Jan 10, 2025

Jan 07, 2025

Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Jan 07, 2025

Jan 06, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World

Jan 06, 2025

Jan 05, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World

Jan 05, 2025

Dec 31, 2024

State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Dec 31, 2024

Dec 28, 2024

TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an inve - Defense World

Dec 28, 2024

Dec 27, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp - Defense World

Dec 27, 2024

Dec 26, 2024

TScan secures $30 million through warrant sale to Lynx1 By Investing.com - Investing.com Nigeria

Dec 26, 2024

TScan Therapeutics Refinances Existing Debt Facility with Silicon Valley Bank - Defense World

Dec 26, 2024

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - The Manila Times

Dec 26, 2024

TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 - StockTitan

Dec 26, 2024

Dec 25, 2024

With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Yahoo Finance

Dec 25, 2024

Dec 24, 2024

TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Dec 24, 2024

Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX) - Defense World

Dec 24, 2024

Dec 23, 2024

Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat

Dec 23, 2024

TScan Therapeutics Secures $52.5M Loan from SVB - TipRanks

Dec 23, 2024

TScan Therapeutics Refinances Existing Convertible Debt - GlobeNewswire

Dec 23, 2024

TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 - StockTitan

Dec 23, 2024

Dec 22, 2024

XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Dec 22, 2024

Dec 17, 2024

2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart

Dec 17, 2024